Santhera Pharmaceuticals has entered into an exclusive license agreement with Nxera Pharma for Agamree (vamorolone) for the treatment of Duchenne muscular dystrophy (DMD) in Australia, Japan, New Zealand and South Korea.[1][5] The license covers the development, production and commercialization of this drug in the countries listed.[1][5] In these states, Nxera will be responsible for obtaining regulatory approval, including potential registration clinical trials, and for the subsequent marketing of the drug.[1][5] Agamree (vamorolone) is indicated for the treatment of DMD, a rare inherited neuromuscular disorder.[1][5] The financial terms of the deal include a total value of up to US$205 million, of which US$40 million is an upfront payment (30 million in cash and 10 million in equity).[1][2][3] In addition, Santhera may receive up to $165 million in regulatory and sales milestones and tiered royalties on net sales in licensed territories.[2][3] Agamree (vamorolone) is already approved for the treatment of DMD in the US, European Union, UK, China, Hong Kong and Canada.[1][4][5]